Experimental HIV vaccine trial ends early – what we know

NCT ID NCT05470400

Terminated ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are not available, but the goal was to gather safety data for future vaccine development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV-1 fusion peptide conjugate vaccine (FP8v1-rTTHC) with Adjuplex adjuvant, alone or with HIV-1 envelope trimer vaccines
What this could lead to: If successful, this could help develop a vaccine that trains the immune system to recognize and fight HIV.
What could go wrong: This was a very early (phase 1) trial focused only on safety and immune response, not on preventing HIV. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Atlanta - Hope Clinic

Atlanta, Georgia, 30308, United States
BIDMC Vcrs [32077]

Boston, Massachusetts, 02115, United States
Columbia P&S CRS [30329]

New York, New York, 30329, United States
New York Blood Center CRS [31801]

New York, New York, 10065, United States
University of Pittsburgh CRS [1001]

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Vaccines to Prevent HIV Infection CRS [31467]

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.